ClinicalTrials.gg
CompletedNCT00343278Updated Apr 14, 2015

Pharmacokinetic Study Of Valaciclovir Hydrochloride Tablets

A Phase 4 interventional study of Valaciclovir Hydrochloride in Virus Diseases, sponsored by GlaxoSmithKline. Completed. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2015-04-14.

Sponsored by GlaxoSmithKline · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
18
Allocation
Non-randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies in Virus Diseases by GlaxoSmithKline — none open to participants now, none under way, none of them phase 3. Virus Diseases · GlaxoSmithKline.

Enrollment
17th of 20
18 · median 177
Started
2005
the only one that year
Phase 4
5 of 20
none open now
Registered
1st of 20
by date

Among the 20 studies in Virus Diseases by GlaxoSmithKline, this one is the 17th largest by enrollment, is the only one that started in 2005, is one of 5 in phase 4, and was the 1st registered.

Virus Diseases

656 studies on the registry are indexed under Virus Diseases; 84 are open to participants now.

Browse Virus Diseases studies →

Open to participants now

None of the 20 studies in Virus Diseases by GlaxoSmithKline is open now. The open studies under Virus Diseases, anywhere →

Who these studies take

Of the 64 Virus Diseases studies recruiting now, 30 (47%) set no upper age limit and 22 (34%) stop at 75 or younger; 28 take children under 18; 27 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 20 studies in Virus Diseases by GlaxoSmithKline as a file.
02

Study summary

Valaciclovir (VACV), the L-valyl ester prodrug of aciclovir (ACV), is extensively converted to ACV and L-valine after oral administration. In subjects with normal renal function, ACV is predominantly eliminated unchanged in the urine, with a small proportion metabolized to 9-carboxymethoxymethylguanine (CMMG). The metabolism of ACV to CMMG is thought to involve aldehyde dehydrogenase (ALDH). On the basis of a high proportion of the Japanese population having low-activity ALDH, it can be hypothesized that the conversion of ACV to CMMG is decreased, thereby leading, in patients with renal impairment, to higher plasma concentrations of ACV. This pilot study was conducted to investigate potential relationships between genetic polymorphisms of ALDH2, an isozyme of ALDH, and the plasma pharmacokinetics (PK) of VACV, ACV and CMMG in subjects with end-stage renal disease on hemodialysis.

03

Conditions studied

  • Virus Diseases

Browse trials for

Keywords

  • Valaciclovir Hydrochloride
  • hemodialysis patient
  • ALDH
  • pharmacokinetics
  • Japanese
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Japanese subjects with chronic renal failure undergoing hemodialysis regularly three times a week for at least 12 weeks prior to the start of the study.

Exclusion criteria

Exclusion criteria:

  • Subjects with current alcohol dependence.
  • Subjects with gastrointestinal dysfunction that may affect drug absorption.
  • Subjects who have received an organ transplant (However, subjects with a corneal transplant or any other organ transplant that may not affect the objectives of the study will be eligible for inclusion in this study).
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
18 participants
06

What researchers measure

Primary outcomes

  1. - The pharmacokinetic parameters for VACV, ACV and CMMG - Relationship between ALDH2 genotypes and the pharmacokinetics of VACV, ACV and CMMG in blood

Secondary outcomes

  1. - Change in blood ACV and CMMG concentrations after a 4-hour hemodialysis session - Safety (adverse events occurring during the study, clinical laboratory tests)

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2005, a primary completion of Aug 2005 and a completion of Aug 2005. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 21, 2006
First posted
Jun 22, 2006
Start
Jul 2005
Primary completionActual
Aug 2005
CompletionActual
Aug 2005
Last update
Apr 14, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 14, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00343278
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Jun 22, 2006
Start date
Jul 2005
Primary completion
Aug 2005
Completion
Aug 2005
Last update
Apr 14, 2015

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Valacyclovir

Start the discussion